Obinutuzumab for the treatment of indolent lymphoma

about

Obinutuzumab for the treatment of indolent lymphoma

Item

http://www.wikidata.org/entity/Q38818380

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Obinutuzumab for the treatment of indolent lymphoma

@en

type

Item

label

Obinutuzumab for the treatment of indolent lymphoma

@en

prefLabel

Obinutuzumab for the treatment of indolent lymphoma

@en

P1476

Obinutuzumab for the treatment of indolent lymphoma

@en

P2093

Jennifer Edelmann

http://www.w3.org/2001/XMLSchema#string

John G Gribben

http://www.w3.org/2001/XMLSchema#string

P2860

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity.

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

P304

1769-1781

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2016-0084

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27117452

http://www.w3.org/2001/XMLSchema#string

P932

5551938

http://www.w3.org/2001/XMLSchema#string

Obinutuzumab for the treatment of indolent lymphoma

about

Obinutuzumab for the treatment of indolent lymphoma

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932